Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06777030Recruiting
Study of exosomes in pancreatic cancer
This study looks at tiny particles called exosomes in pancreatic cancer. Researchers want to understand how exosomes may help the cancer grow, which could lead to better treatments in the future.
BolognaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Los Angeles, CaliforniaAges 18–100 - NCT06781242Recruiting
Genes and symptoms in inherited bile flow problems
This study looks at how genes affect bile flow problems in the liver. If you have a rare genetic condition like PFIC, researchers want to understand your specific type better by comparing your genes to your symptoms.
Bologna, BolognaAges 18 years+ - NCT06793709Recruiting
Study of Tasfygo for bile duct cancer with FGFR2 gene change
This study is watching people with a certain type of bile duct cancer that has a specific gene change (FGFR2 fusion). It looks at what happens when they take the drug Tasfygo after their cancer did not respond to chemotherapy.
TokyoAges Any age - NCT06794645RecruitingPhase 2
Pembrolizumab and Pemetrexed for Growing Chordoma
This trial tests two drugs—pembrolizumab (Keytruda) and pemetrexed—for people with chordoma that has continued to grow. The goal is to see if the combination can slow or stop the tumor. You'll need to be in fairly good health and able to take other medicines (folic acid and vitamin B12) to protect your body from side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT06794684Recruiting
Watching Plaque in Heart Arteries Over Time
This study uses CT scans and special camera images inside your arteries to watch how plaque buildup in heart arteries changes over time. It may help you understand your risk and guide future treatment.
ShanghaiAges 18 years+ - NCT06800651RecruitingPhase 2
A new drug for fast-growing polycystic kidney disease
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
Beijing, Beijing MunicipalityAges 18–55 - NCT06815029RecruitingPhase 1
Modified immune cells for recurrent brain cancer
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Duarte, CaliforniaAges 18 years+ - NCT06816446Recruiting
Do special glasses slow myopia in children?
This trial tests whether special Rodenstock glasses can slow down the worsening of nearsightedness (myopia) in children. It's for kids aged 6 to 12 who have never had myopia treatment before.
SingaporeAges 6–12 - NCT06816563Recruiting
Predicting success of turning a breech baby
This trial studies a special ultrasound measurement called the 'breech progression angle' to see if it can predict whether a doctor can safely turn a breech baby into a head-down position using gentle pressure on the belly (external cephalic version).
Bologna, BolognaAges 18–45 - NCT06820398Recruiting
Exercise program for kids with cerebral palsy
This trial tests a special exercise program that combines strength training with resistance for children and teens with cerebral palsy. The goal is to see if it helps improve movement, strength, and daily function.
ValenciaAges 10–18 - NCT06824064RecruitingPhase 2
RBS2418 for advanced metastatic colorectal cancer
This trial tests a new drug called RBS2418 for people with advanced colorectal cancer that has spread and is getting worse, even after other treatments have stopped working. The goal is to see if RBS2418 can help control the cancer.
Newark, DelawareAges 18 years+ - NCT06838676RecruitingPhase 2
ACT001 for DIPG and H3K27-altered high-grade gliomas
This trial tests a drug called ACT001 for people with diffuse intrinsic pontine glioma (DIPG) or certain high-grade gliomas that have a specific genetic change (H3K27-altered). It includes two groups: one for newly diagnosed DIPG after radiation, and another for progressive or recurrent disease.
Aurora, ColoradoAges 1–39 - NCT06839144RecruitingPhase 2
Medications before surgery to slow ovarian cancer growth
This trial tests whether giving two common medications before and after surgery can slow the growth of ovarian cancer. The medications may help reduce stress signals that could make cancer spread faster during surgery.
Ramat GanAges 20–85 - NCT06839469Recruiting
Walking study for rare muscle and nerve conditions
This study looks at how children and teens with Duchenne muscular dystrophy (DMD) or spinal muscular atrophy (SMA) walk, by having them do walking tests while wearing sensors. The goal is to find better ways to track how these diseases progress and how treatments work over time, without needing blood tests or scans.
Palo Alto, CaliforniaAges 5 years+ - NCT06843005Recruiting
Heart CT scan study for plaque changes in mild coronary disease
This study uses repeat CT scans of the heart to see how plaque buildup changes over time in people with mild, non-blocking coronary artery disease. It may help doctors decide on better treatments to prevent future heart problems.
Nanjing, JiangsuAges 18–80 - NCT06844643Recruiting
Axial spondyloarthritis progression study in China
This study tracks how axial spondyloarthritis progresses over time in Chinese patients. It helps doctors understand the natural course of the disease and improve care.
BeijingAges 18 years+ - NCT06845410Recruiting
INR-CAD: inflammation-related coronary artery disease study
This study follows people who have both coronary artery disease (narrowed heart arteries) and signs of chronic inflammation to learn more about their condition, current treatments, and outcomes. It helps doctors understand how best to care for patients like you.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06850168Recruiting
Can special glasses slow down nearsightedness in children?
This trial tests a new type of spectacle lens designed to slow the progression of nearsightedness (myopia) in children. If your child is between 6 and 10 years old, has mild to moderate nearsightedness, and is willing to wear glasses full-time for two years, this study may be a good fit.
SingaporeAges 6–11 - NCT06855368Recruiting
Biomarkers for tracking dementia progression
This study looks at biological markers to monitor how dementia changes over time. It may help understand the disease better in people with early Alzheimer's or mild cognitive impairment.
RomaAges 18 years+ - NCT06856213RecruitingPhase 2
Cetuximab with or without weekly paclitaxel for head and neck cancer
This study tests whether adding the chemotherapy drug paclitaxel (Taxol) to the targeted therapy cetuximab (Erbitux) is more effective than cetuximab alone for head and neck cancer that has progressed after initial immunotherapy and chemotherapy. Researchers want to see if the combination can help shrink tumors or slow the disease.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT06863194RecruitingPhase 1/Phase 2
Probiotics and kidney disease progression trial
This trial tests whether taking a probiotic supplement can slow down the decline of kidney function in people with moderate chronic kidney disease (CKD stages 3 and 4). If you have stable kidney disease and are not already taking probiotics, joining this study could help researchers find a new way to protect your kidneys.
Al Mansurah, DakahliyaAges 18 years+ - NCT06863311RecruitingPhase 2
Trial of zanzalintinib with immunotherapy for advanced kidney cancer
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06878664RecruitingPhase 3
Lu177-Dotatate vs standard care for slow-growing midgut neuroendocrine tumors
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Caen, CaenAges 18 years+
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 718 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.